Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-27T09:47:50.093Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and systemic tolerability of mometasone furoate and betamethasone sodium phosphate

Published online by Cambridge University Press:  08 March 2006

Rajan S. Patel ,
Steve R. Shaw ,
A. Michael Wallace  and
Gerald W. McGarry
Rajan S. Patel
Affiliation:
Departments of Otolaryngology, North Glasgow Hospitals University NHS Trust, UK.
Steve R. Shaw
Affiliation:
School of Mathematics and Statistics, University of Plymouth, UK.
A. Michael Wallace
Affiliation:
Clinical Biochemistry, North Glasgow Hospitals University NHS Trust, UK.
Gerald W. McGarry
Affiliation:
Departments of Otolaryngology, North Glasgow Hospitals University NHS Trust, UK.
Get access Rights & Permissions [Opens in a new window]

Abstract

This study evaluates the efficacy and systemic tolerability of licensed doses of mometasone furoate (Nasonex®) and betamethasone sodium phosphate (Betnesol®) in allergic chronic rhinosinusitis patients. It also assesses the diagnostic accuracy of morning salivary cortisol (MSC) concentrations to screen for adrenal suppression inthese patients.

Forty-eight patients were prospectively randomized to two treatment limbs. Symptom scores and adrenal function assessments were performed immediately prior to commencement and at the end of treatment.

One (4 per cent) mometasone furoate and 14 (58 per cent) betamethasone sodium phosphate patients developed biochemical evidence of adrenal suppression. There were statistically significant (p < 0.005) reductions in symptom scores following treatment, but no significant difference (p > 0.05) between the drug groups regarding post-treatment symptom scores. As a screening tool for iatrogenic adrenal suppression, MSC had a sensitivity of 100 per cent and a specificity of 97 per cent.

This study demonstrates the high risk of developing adrenal suppression secondary to betamethasone sodium phosphate therapy. The salivary cortisol assay is an accurate tool for monitoringadrenal function and is ideally suited to the out-patient setting.

Keywords

HypersensitivitySteroidsDisease ManagementAdrenal Gland HypofunctionSalivaToxicity TestsSensitivity and Specificity
Type
Research Article
Information
The Journal of Laryngology & Otology , Volume 118 , Issue 11 , November 2004 , pp. 866 - 871
Copyright
© 2004 Royal Society of Medicine Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)